Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Long-Term Safety and Effectiveness of Minzasolmin and Iodine Ioflupane (123I) in Patients with Parkinson's Disease

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Parkinson's disease, a condition that affects movement and can cause tremors, stiffness, and difficulty with balance and coordination. The study is evaluating a treatment called minzasolmin, also known by its code name UCB0599. This treatment is being tested to see how safe it is and whether it works effectively over a long period for people with Parkinson's disease. Another substance used in the study is iodine ioflupane (123I), which is a chemical used in imaging to help understand changes in the brain.

The purpose of the study is to assess the effects of minzasolmin on the brain in participants who have been newly diagnosed with Parkinson's disease. Participants in the study will receive either minzasolmin or a placebo, which looks like the treatment but does not contain the active substance. The study will follow participants over time to monitor the safety and effectiveness of the treatment. Participants will undergo various assessments, including imaging tests, to track changes in their condition.

This study is an extension of a previous study, and it aims to provide more information about the long-term use of minzasolmin in treating Parkinson's disease. The study will help researchers understand how the treatment affects the brain and whether it can improve symptoms or slow the progression of the disease. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Screening and baseline visit

    Upon joining the study, the first step is the screening and baseline visit. During this visit, a urine pregnancy test is conducted to confirm a negative result before the first dose of the investigational medicinal product (IMP).

    Participants must have completed the treatment period of the previous study, PD0053, and the baseline visit for this study should occur no later than four weeks after the end of treatment visit in PD0053.

  2. Step 2

    Treatment period

    During the treatment period, participants will receive the investigational medicinal product, minzasolmin (UCB0599), in the form of a capsule for oral use. The dosage and frequency will be determined by the study protocol.

    Participants are required to use contraception during the treatment period and for at least 90 days after the last dose of the IMP. Women of childbearing potential must follow contraceptive guidance during the treatment period and for at least one month after the last dose.

  3. Step 3

    Follow-up visits

    Throughout the study, participants will attend regular follow-up visits to monitor their health and the effects of the treatment. These visits will include assessments such as imaging tests to evaluate brain function and other health checks.

    Participants will be monitored for any adverse events or side effects, and the study team will adjust the treatment as necessary to ensure safety and tolerability.

  4. Step 4

    End of study

    At the end of the study, participants will undergo a final assessment to evaluate the long-term efficacy, safety, and tolerability of the treatment.

    The study is estimated to conclude by April 2027, and participants will be informed of the results and any further steps if needed.

Who can join the trial?

6 criteria

  • The participant must have completed the Treatment Period of a previous study called PD0053. The next visit for this study should be no later than 4 weeks after the end of the previous study, unless there is a justified reason approved by the study team.
  • A male participant must agree to use contraception during the study and for at least 90 days after the last dose of the study medication. He must also agree not to donate sperm during this time.
  • A female participant can join if she is not pregnant, not breastfeeding, and meets one of the following conditions:
    • She is not able to become pregnant.
    • If she can become pregnant, she agrees to use contraception during the study and for at least 1 month after the last dose of the study medication. She must have a negative pregnancy test before starting the study.
    • If a female participant uses oral contraception, she must also use an additional barrier method (like a condom) during the study because the study medication might affect how well the oral contraception works.
    • The participant must be able to give signed informed consent, which means they understand the study and agree to follow the rules and restrictions.

Who cannot join the trial?

10 criteria

  • Patients who do not have a diagnosis of Parkinson's disease cannot participate.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older adults.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not willing or able to follow the study procedures cannot participate.
  • Patients who have any other medical condition that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who are taking certain medications that might interfere with the study cannot participate.
  • Patients who have participated in another clinical trial recently cannot participate.
  • Patients who have a history of drug or alcohol abuse cannot participate.
  • Patients who have a known allergy to the study medication cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

UCB0599 is a medication being studied for its potential to help people with Parkinson's disease. Parkinson's disease is a condition that affects the brain and can cause problems with movement, balance, and coordination. This medication is being tested to see if it can slow down or change the way the disease affects the brain over time. The study is looking at how the medication works in people who start taking it early in their diagnosis compared to those who start taking it later. The goal is to understand if starting the medication earlier can have better effects on the brain and help manage the symptoms of Parkinson's disease more effectively.

What is already known about the treatment

UCB0599 – UCB0599 is an investigational medication administered orally, designed to treat Parkinson's disease. It is currently being studied in clinical trials to assess its long-term effectiveness, safety, and tolerability for individuals with this condition. The main therapeutic goal of UCB0599 is to slow down the progression of Parkinson's disease by targeting specific brain changes associated with the disease. At the molecular level, it works by inhibiting certain proteins that contribute to the degeneration of brain cells. UCB0599 falls under the pharmacological classification of neuroprotective agents, which are substances aimed at protecting nerve cells from damage.

Investigated diseases

Parkinson’s disease – Parkinson’s disease is a progressive neurological disorder that affects movement. It is characterized by tremors, stiffness, and difficulty with balance and coordination. The disease progresses gradually, often starting with barely noticeable tremors in one hand. As it advances, individuals may experience slower movement, muscle rigidity, and impaired posture. Over time, the symptoms can become more severe, affecting daily activities and leading to difficulties in walking and talking. The progression of Parkinson’s disease varies among individuals, with some experiencing rapid changes and others having a slower progression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-500424-30-00Protocol codePD0055Estimated enrolment414 patientsSponsorUCB Biopharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).